



Nonpharmacological Approach to Managing Atrial Fibrillation: A Review

**Francis C. Ifiora ^a, Ginikachukwu M. Agudosi ^b,
Chinwendum U. Ekpemiro ^c, Valentine C. Keke ^d,
Pedro Okoh ^e, Abiola Y. Oyesile ^f, Linda A. Mbah ^g,
Ngozi T. Akueme ^h, Oyewole Emmanuel Akanle ⁱ,
Romanus Anebere ^j, Moses, Chukwuebuka Odoeke ^k,
Yetunde Ishola ^l and Okelue E. Okobi ^{m*}**

^a Department of Pharmacy, University of Texas Health Science Center at Houston, Houston, USA.

^b Department of Internal Medicine, Trinity School of Medicine, Warner Robins, USA.

^c Department of Surgery, Federal Medical Centre, Umuahia, Nigeria.

^d Department of Internal Medicine, University of Nigeria, Enugu, Nigeria.

^e Department of Emergency Medicine, Lancashire Teaching Hospital, Preston, England.

^f Department of Medicine, Dnipropetrovsk Medical Institute, Dnipropetrovsk, Ukraine.

^g Department of Internal Medicine, Veterans Affairs, Indiana, USA.

^h Department of Dermatology, University of Medical Sciences (UNIMEDTH), Ondo State, Nigeria.

ⁱ Ladoko Akintola University of Technology, Ogbomosho, Oyo-State, Nigeria.

^j Imo State University, Owerri, Imo State, Nigeria.

^k University of Nigeria Nsukka, Nigeria.

^l Oba Okunade Sijuade College of Health Sciences Igbinedion University, Okada, Edo State, Nigeria.

^m Department of Family Medicine, Larkin Community Hospital, Palm Springs Campus, Miami, USA.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/CA/2023/v12i4364

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/106522>

Systematic Review Article

Received: 18/07/2023

Accepted: 22/09/2023

Published: 23/09/2023

*Corresponding author: E-mail: drokelue.e.okobi@gmail.com;

ABSTRACT

Background: AF's global prevalence underscores its significance as a cardiac rhythm disorder that disrupts atrial activity, impairing normal cardiac function. Over five decades of study have illuminated the pathophysiological mechanisms underlying AF, including insights into re-entrant waves and macro-reentrant circuits. The emergence of non-uniform conduction patterns and bidirectional block regions has further enriched our understanding. Risk factors contributing to AF development encompass cardiovascular conditions, advanced age, and atrial structural changes. With its implications on stroke risk and cardiovascular health, AF has become a growing public health concern. The focus on AF epidemiology has expanded, with attention on the relationship between left atrial size and AF development. Individuals with larger left atria exhibit a heightened risk. Additionally, the elevated stroke risk associated with AF has been consistently documented.

To optimize clinical management, distinctions are drawn between chronic and paroxysmal AF, as well as the presence of structural heart disease. Mapping techniques have revealed insights into "atrial remodeling" and AF pathology. In managing AF, controlling heart rate, preventing clot formation, and restoring sinus rhythm are principal objectives. This article categorizes AF into acute, chronic, stable, or unstable forms, tailoring management approaches accordingly. While pharmacological interventions have shown efficacy, their limitations drive the exploration of nonpharmacological strategies. Approaches range from medications to cardioversion, including electrical and pharmacological methods.

Objective: This paper aimed to provide a comprehensive exploration of non-pharmacological approaches to AF management.

Methodology: This paper employed a structured methodology. This method involved a literature review, data synthesis, and critical analysis. During the literature review phase, we systematically searched electronic databases (PubMed, MEDLINE, Embase, and Google Scholar) for studies published from 1960 to 2023. Specific keywords and phrases such as "atrial fibrillation," "non-pharmacological interventions," "electrical cardioversion," "catheter ablation," "lifestyle modifications," "autonomic modulation," "left atrial appendage closure," and "exercise" were used. Our inclusion criteria encompassed studies addressing various non-pharmacological approaches for AF management, including observational studies and randomized controlled trials.

Result: The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies according to type, we conducted a detailed review of the remaining 350 studies. We categorized them into various types based on study design, methodology, and focus. We then also excluded studies with duplicate ideas and finally included 103 studies that addressed the objective of our research plan. (See reference list [1-103]).

Conclusion: This reviewed a number of non-pharmacological approaches including electrical cardioversion, catheter ablation, lifestyle modifications, autonomic modulation, left atrial appendage closure, and exercise, the paper delves into each method's advantages, potential risks, techniques, and efficacy. By offering this extensive overview, the article contributes to the expanding repository of knowledge on non-pharmacological approaches for AF management. These approaches offer potential for unique management of atrial fibrillations or in addition to pharmacologic management, may improve patient survivability or reduce complication outcomes.

In the management of Atrial fibrillation, choice between rhythm and rate control, lifestyle modifications, and patient adherence to treatment plans are critical factors influencing outcomes are factors to consider. Emerging therapies offer promise, but timely diagnosis, individualized care, and ongoing monitoring remain essential to improving AF patients' overall prognosis.

Keywords: *Cardiovascular health; left atrial size; pathophysiological mechanisms; af management; cardiac arrhythmia; non-pharmacological approaches; atrial fibrillation.*

1. INTRODUCTION

Atrial fibrillation stands as a widespread cardiac arrhythmia afflicting countless individuals

globally. As the foremost prevalent cardiac rhythm disorder, atrial fibrillation yields irregular and swift atrial activity, thereby impeding efficient heart contraction [1]. Over the past five decades,

extensive research has been devoted to comprehending the pathophysiological underpinnings of this condition. This exploration led to the initial hypothesis of simultaneous multiple re-entrant waves as the driving mechanism [1]. However, this hypothesis underwent re-evaluation due to subsequent revelations [1]. Notably, human atrial fibrillation exhibited atrial re-entry, and macro-reentrant circuits within the atrial myocardium were identified as the culprits for the complete spectrum of canine atrial fibrillation-related arrhythmias [2]. Moreover, investigations unveiled non-uniform conduction encircling areas with bidirectional blocks in both atria, resulting in discrete wavefronts during human atrial fibrillation [2]. These discoveries have markedly augmented our comprehension of atrial fibrillation and its underlying pathophysiological mechanisms [1]. Risk factors associated with atrial fibrillation include cardiovascular conditions like mitral valve disease, left ventricular dysfunction, and atrial enlargement [3]. For patients with non-rheumatic atrial fibrillation, warfarin is often prescribed [4]. Research indicates that advanced age escalates the susceptibility to atrial fibrillation [5]. Furthermore, any alterations in atrial structure or function are thought to contribute to its onset [6]. The condition has evolved into a predominant public health challenge in Western nations [7]. Notably, an enlarged left atrium has been linked to atrial fibrillation development [8]. Additionally, the risk of stroke escalates fivefold in those afflicted with atrial fibrillation [9].

Recent times have witnessed heightened attention to atrial fibrillation as a pressing public health concern. This stems from its association with heightened stroke and cardiovascular risks [7]. Consequently, the epidemiology of atrial fibrillation has emerged as a pivotal research domain [6]. One facet of atrial fibrillation epidemiology scrutinized is the correlation between left atrial size and its onset [8]. Scientific inquiry has indicated that individuals with larger left atria face an elevated risk of atrial fibrillation incidence [9]. Furthermore, the likelihood of stroke among individuals with atrial fibrillation is five times greater compared to their counterparts without the condition [2]. Clinically, distinguishing between chronic and paroxysmal atrial fibrillation is crucial [10], as is identifying those with or without structural heart abnormalities [3]. Elderly age has also been identified as a predisposing factor for atrial fibrillation [5]. Researchers have employed mapping techniques to elucidate the

condition's pathology [4], yielding insights into the role of "atrial remodeling" in its emergence [1].

Efforts to manage atrial fibrillation predominantly revolve around heart rate control, stroke prevention, and, in select cases, restoration of a normal sinus rhythm. Atrial fibrillation can be categorized into acute or chronic, stable or unstable forms, with management strategies differing slightly for each scenario while encompassing pharmacological and non-pharmacological interventions. Treatment goals may include rate or rhythm stabilization, long-term prevention of recurrence, or addressing complications arising from irreversible causes. Conventional pharmacological approaches have proven effective in managing atrial fibrillation, yet they carry inherent limitations and side effects. Consequently, non-pharmacological strategies have gained prominence. Medications such as anti-arrhythmics and anticoagulants are often employed to achieve therapeutic objectives.

This manuscript aims to offer a comprehensive overview of non-pharmacological strategies in atrial fibrillation management. The exploration encompasses electrical cardioversion, catheter ablation, lifestyle modifications, autonomic modulation, left atrial appendage closure, and exercise. The paper delves into the merits and drawbacks of each approach, the techniques employed, and their efficacy in atrial fibrillation management. This endeavor seeks to contribute to the expanding repository of knowledge concerning non-pharmacological atrial fibrillation management approaches.

2. METHODOLOGY

To achieve the objective of providing a comprehensive overview of non-pharmacological management approaches for atrial fibrillation (AF), a structured methodology was employed. This methodology encompassed literature review, data synthesis, and critical analysis, all of which collectively facilitated a thorough examination of the various non-pharmacological interventions available for managing AF. The literature review phase involved conducting a systematic and exhaustive search across a range of electronic databases, including PubMed, MEDLINE, Embase, and Google Scholar. This search encompassed studies that had been published from 1960 to 2023. The search strategy incorporated specific keywords and phrases such as "atrial fibrillation," "non-

pharmacological interventions," "electrical cardioversion," "catheter ablation," "lifestyle modifications," "autonomic modulation," "left atrial appendage closure," and "exercise." By using these terms in combination, the goal was to retrieve articles that were directly relevant to the topic. In the subsequent data selection and inclusion criteria phase, articles were meticulously screened based on predetermined criteria. The inclusion criteria focused on studies that specifically addressed non-pharmacological approaches for the management of atrial fibrillation, covering a wide spectrum of interventions. This encompassed both observational studies and randomized controlled trials.

On the other hand, exclusion criteria were applied to studies that exclusively concentrated on pharmacological interventions, those that lacked sufficient detail regarding their methodology, and those that were not available in English. Pertinent data from the selected studies were carefully extracted during the data extraction and synthesis phase. This encompassed details about the study design, sample size, patient demographics, interventions' specifics, measured outcomes, and results obtained. The collected data were then synthesized to provide a comprehensive and coherent overview of the efficacy and safety of the diverse non-pharmacological interventions in the management of atrial fibrillation. Critical analysis followed, involving a rigorous assessment of the selected studies to ascertain their methodological quality and any potential biases. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach was utilized to offer a systematic method for evaluating the quality of evidence associated with each intervention. This critical analysis served as a foundation for evaluating the reliability and applicability of the findings.

The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies according to type, we conducted a detailed review of the remaining 350 studies. We categorized them into various types based on

study design, methodology, and focus. We then also excluded studies with duplicate ideas and finally included 103 studies that addressed the objective of our research plan. (See reference list [1-103]).

The synthesized data were subsequently presented and organized, categorizing the interventions, such as electrical cardioversion, catheter ablation, lifestyle modifications, autonomic modulation, left atrial appendage closure, and exercise. For each intervention, the benefits, risks, and effectiveness were discussed, all based on the findings from the studies that had been included. In the discussion and conclusion phase, the critical analysis and data synthesis results were contextualized within the existing body of literature. This involved a thoughtful exploration of the strengths and limitations inherent in the reviewed studies and an examination of the implications of the findings for clinical practice. The paper concluded by summarizing the key insights gleaned and outlining potential avenues for further research within the realm of non-pharmacological management approaches for atrial fibrillation.

3. REVIEW

3.1 Electrical Cardioversion

Electrical cardioversion is a non-pharmacological approach to managing atrial fibrillation [11]. This technique is primarily utilized to reinstate regular heart rhythm in patients experiencing atrial arrhythmias, such as atrial fibrillation or atrial flutter, which lead to irregular atrial contractions. The procedure involves delivering a synchronized electrical shock to the heart, often timed with the QRS complex on an electrocardiogram. The objective is to reset the heart's electrical activity and reestablish a normal sinus rhythm. Notably, the energy level applied during electrical cardioversion is typically lower than in defibrillation and is adjusted based on the specific arrhythmia and the patient's condition.

Electric cardioversion stands as the preferred method for restoring sinus rhythm, demonstrating reported efficacy rates ranging from 75% to 87% [12,13]. It is frequently the initial course of action for individuals affected by atrial fibrillation. Nevertheless, the challenge of maintaining long-term sinus rhythm remains, as numerous patients experience relapses after the procedure [12]. To address this concern, a study was conducted to investigate the impact of

administering Propafenone prior to electrical cardioversion in cases of chronic atrial fibrillation [11]. The study results indicated that Propafenone did not influence the mean defibrillation threshold or the rate of successful arrhythmia conversion [11]. However, it was observed that Propafenone decreased the incidence of atrial fibrillation recurrence shortly after the shock, leading to a higher proportion of patients being discharged from the hospital in sinus rhythm [11]. These findings suggest the potential benefits of utilizing Propafenone as a complement to electrical cardioversion in atrial fibrillation management [11]. Moreover, this approach eliminates the hemodynamic complications linked with relapses and the risks associated with prophylactic anti-arrhythmic drug therapy [12], which offers an additional advantage. Despite this, a comparison between the efficacy of electrical cardioversion and anti-arrhythmic drugs demonstrated that initiating treatment with anti-arrhythmic drugs was more effective than starting with electrical cardioversion [14]. Furthermore, the initial success rate for cardioversion was found to be similar for both chemical and electrical approaches [14]. The ultimate aim is to transform irregular atrial arrhythmias into a sinus rhythm, making it a non-emergent intervention.

However, it's crucial to note that the application of electrical cardioversion comes with potential risks, such as embolization and thromboembolism [15]. Occurrences of embolic events within 30 days of cardioversion were reported in 0.9% of patients, with a lower incidence observed in patients under therapeutic levels of oral anticoagulation [15]. Variables such as age, left ventricular systolic dysfunction, diabetes mellitus, and hypertension were identified as factors that increased the risk of embolization [15]. Notably, hypertension was independently associated with a heightened risk of early embolization post-cardioversion, although effective anticoagulation mitigated the risk [15]. However, the efficacy of heparin as monotherapy in preventing embolization remains uncertain [15]. Additionally, it was found that embolization could still occur after cardioversion even without a thrombus, although oral anticoagulants contributed to reducing the risk [15]. While embolic events after cardioversion were infrequent [15], it's evident that the application of electrical cardioversion techniques remains a valid option for managing atrial fibrillation.

Furthermore, research underscores the efficacy of electrical cardioversion as an effective technique for atrial fibrillation treatment [16]. Studies advocate for anticoagulation before electrical cardioversion, as it significantly diminishes the likelihood of thromboembolic complications [16]. Patients who do not receive anticoagulation pre-treatment face a higher risk of thromboembolic complications following electrical cardioversion [16], a risk that is especially pronounced in patients with elevated stroke risk. It's worth noting that patients with a low stroke risk did not experience thromboembolic complications within 30 days post-cardioversion [16]. Nonetheless, no substantial distinctions were noted regarding bleeding complications between patients who underwent cardioversion with or without anticoagulation [16]. This emphasizes anticoagulation pre-treatment's critical role in mitigating the risk of thromboembolic complications. Moreover, hypertension emerged as an independent risk factor for early embolization after cardioversion [16], highlighting its significance in the context of embolic events. Despite the proven efficacy of electrical cardioversion for atrial fibrillation treatment, using anticoagulation pre-treatment remains pivotal in minimizing the risk of thromboembolic complications.

3.2 Catheter Ablation (CA)

Catheter ablation is a pivotal technique employed in managing atrial fibrillation (AF) [17]. This intricate procedure involves the utilization of a radiofrequency catheter, cryo-balloon, and contact force catheter [17]. However, its complexity is accompanied by the potential for life-threatening complications, including stroke, tamponade, and atrio-esophageal fistula [17]. Fortunately, recent data indicates a decreasing trend in the complication rate of AF ablation, with a recent study reporting a major complication rate of 0.8% [17]. The success rates of catheter ablation are multifaceted, contingent upon the type of AF, concurrent structural heart conditions, comorbidities, and the criteria for defining success [17]. Even after approximately 5 years of follow-up, the long-term success rate of catheter ablation remains at nearly 80% [17]. Per the HRS/EHRA/ECAS Consensus Document, a 3-month-blanking period post AF ablation is recommended, wherein recurrences of atrial arrhythmia are not classified as procedure failures [17]. Moreover, research highlights the cost-effectiveness of this technique in patients

with symptomatic paroxysmal AF compared to anti-arrhythmic drug therapy [17].

Central to this approach is the creation of ablation lesions through a transvenous irrigated radiofrequency ablation catheter introduced via the femoral vein [17]. Furthermore, innovative ablation catheters have emerged, furnishing real-time feedback on the degree and orientation of force applied when the catheter contacts the atrial wall [17]. This dynamic technique not only reduces healthcare resource consumption but also mitigates the risk of stroke [17].

Exploration into developing magnetic resonance-based ablation for managing atrial fibrillation remains a subject of ongoing research [17]. However, the text does not elaborate on the associated risks connected to this technique [17]. Although the optimal ablation strategy for patients with non-paroxysmal AF continues to be debated due to a lack of compelling evidence, a comparative study spanning three patient subsets demonstrated no disparities in success rates and complication occurrences [17]. In summary, catheter ablation has proven its superiority over anti-arrhythmic drug therapy and continues to stimulate investigations into alternative energy sources like MRI and laser light-based ablation systems for effective atrial fibrillation management [17].

Despite its growing popularity as a treatment avenue for atrial fibrillation (AF), the catheter ablation procedure is not without risks and potential complications [17]. Among these, vascular injury ranks as the most prevalent, with an occurrence rate ranging from 0.5% to 2% [17]. Meanwhile, the incidence of stroke, while less frequent than vascular injury, ranges from 0.3% to 1% [17]. Other potential complications encompass cardiac tamponade, a condition characterized by fluid accumulation within the pericardial cavity, culminating in reduced cardiac output and potential cardiac arrest. This rare complication surfaces in 0.5% to 2% of cases [17].

Moreover, the procedure is linked to the possibility of infection, arrhythmias, and embolization. However, the applicability of AF ablation in elderly patients raises uncertainties regarding safety and efficacy [17]. Additionally, patients aged 75 years and above exhibited a lower likelihood of undergoing repeat procedures, instead opting for continued anti-arrhythmic drug therapy [17]. Notwithstanding

these risks, the catheter ablation procedure has demonstrated its superiority over anti-arrhythmic drug therapy in curbing AF recurrence [17].

3.3 Surgical Ablation (Maze Procedure)

The Cox-Maze procedure is a minimally invasive surgical remedy for atrial fibrillation (AF) renowned for its remarkable effectiveness and safety [18]. This technique entails strategically carving incisions or deploying burns on the atria of the heart to disrupt erratic electrical signals [18]. The "cut and sew" Cox-Maze procedure has been the gold standard for AF treatment since 1987 [19]. Initially conducted using a scalpel, ablation technology advancements have streamlined the procedure, enabling the integration of bipolar radiofrequency energy to replace numerous incisions [20]. A study involving 335 patients who underwent the Cox-Maze procedure [21] delved into comparing the Cox-Maze III and Cox-Maze IV procedures through propensity analysis [19]. The findings underscored superior outcomes associated with the Cox-Maze IV procedure [19]. In this study, 242 patients underwent the Cox-Maze procedure between April 1992 and July 2005 [19]. Logistic regression analysis was employed to ascertain covariates among 7 baseline patient variables [19]. Demonstrating its efficacy, the Cox-Maze procedure emerged as a potent surgical intervention for AF treatment [21], targeting medically refractory symptomatic atrial fibrillation and potentially combined with other cardiac interventions [22]. Moreover, this procedure often achieves curative results, albeit occasionally necessitating postoperative atrial pacemakers [22].

A systematic review compared three minimally invasive stand-alone surgical ablation methods for AF: the endocardial Cox-Maze procedure, epicardial surgical ablation, and a hybrid epicardial surgical and catheter-based endocardial ablation procedure [18]. The endocardial Cox-Maze procedure entails incisions and ablation lines to isolate pulmonary veins from the left atrium and restore atrioventricular synchrony [18]. In contrast, the epicardial surgical ablation incorporates bipolar radiofrequency energy and cryoablation as ablative sources to craft additional lines in both the left and right atria. Meanwhile, the hybrid approach seeks to enhance electrophysiological validation of endovascular conduction block [18]. The results spotlight operative mortality rates of 0%, 0.5%, and 0.9% for the endocardial Cox-

Maze, epicardial surgical ablation, and hybrid surgical ablation groups, respectively [18]. Moreover, the 1-year success rate for the minimally invasive endocardial Cox-Maze procedure ranged from 87.0% (without anti-arrhythmic medications) to 90.5% (with anti-arrhythmic medications) [18]. The Cox-Maze procedure emerged as the most efficacious minimally invasive surgical ablation strategy for stand-alone AF treatment [18]. Enhancing the substrate, including biatrial ablation and additional lines in the left atrium, proved instrumental in boosting success rates, particularly in the non-paroxysmal AF subgroup [18]. Employing these strategies yielded 12-month sinus rhythm restoration rates of 93%, 80%, and 70% for the endocardial Cox-Maze, epicardial surgical ablation, and hybrid surgical ablation groups, respectively [18].

The application of the maze procedure to mitigate stroke risk and other complications stemming from atrial fibrillation (AF) has garnered substantial interest within the medical research domain [18]. The Cox-Maze procedure, combining cardiopulmonary bypass with lesion-based ablation, has demonstrated superior effectiveness over epicardial approaches in curtailing perioperative stroke risk [18]. Nonetheless, this approach also appears associated with a heightened rate of permanent pacemaker placement, primarily due to its use in non-paroxysmal AF cases [18]. Moreover, the modified CryoMaze III procedure has gained prominence in patients necessitating mitral valve surgery or similar interventions [22]. Significantly less invasive than the Cox-Maze procedure, this technique has shown a decreased incidence of postoperative strokes in comparison to the control group [22]. Further underscoring its efficacy, freedom from atrial fibrillation off anti-arrhythmics reached 77% with an average follow-up period of 3.0 ± 2.1 years, while achieving 90% for the 3-minute ablation group at the 12-month mark [22]. Collectively, these findings underscore the efficacy of the CryoMaze III procedure as an effective AF treatment. In essence, the maze procedure stands as a viable avenue for mitigating stroke risk and other related complications inherent in atrial fibrillation.

3.4 Pulmonary Vein Isolation (PVI) Method

The catheter-based Pulmonary Vein Isolation (PVI) method stands as a pivotal procedure in the management of atrial fibrillation (AF). It

functions by creating isolation around the pulmonary veins, which are often the culprits behind the aberrant electrical signals responsible for triggering AF. This technique, effectively disrupting these anomalous signals, is recognized as a potential curative solution for AF [23]. PVI not only aids in managing and preventing AF but also holds promise as a means of achieving a cure, even when paired with additional strategies such as superior vena cava isolation (SVCI) for investigation into its efficacy among symptomatic patients with persistent atrial fibrillation (PAF) undergoing ablation [24]. In various AF populations, PVI serves as the foundational cornerstone for ablation [23], frequently harmonizing with a focused strategy targeting the cavotricuspid isthmus [25]. Comparative studies have explored its efficacy against CFAE ablation, encompassing both paroxysmal and nonparoxysmal AF patients [23]. One study specifically assessed the combined approach of PVI plus CFAE ablation versus PVI alone, evaluating pooled mean differences and risk ratios [23]. While the combination yields advantages for nonparoxysmal AF patients, it's accompanied by extended fluoroscopy and procedure times [23]. Although the true merit of adjunct CFAE ablation alongside PVI remains somewhat ambiguous, it's postulated that this amalgamation could enhance freedom from atrial arrhythmia in nonparoxysmal AF patients [23]. It's pertinent to note that antral isolation yields superior outcomes compared to ostial ablation within the realm of AF ablation [23]. Furthermore, the risks linked to atrial flutter ablation remain notably low, with serious complications occurring in 1% or less of cases [25]. Thus, adopting the PVI method for AF management proffers a multitude of merits, encompassing enhanced freedom from atrial arrhythmia in nonparoxysmal AF patients [23], and efficacious prevention strategies for AF [25].

However, despite its potential as a curative approach to AF, the PVI method does entail associated risks. A study systematically gauged the anticipated risk tied to the PVI method, revealing that a sequential ablation pathway presented a lower anticipated risk compared to a combined ablation approach [25]. On average, PVI risk was quantified at 2%, while the composite ablation strategy exhibited higher cumulative risk when PVI procedural risk exceeded atrial flutter ablation risk by 24.6% [25]. Importantly, the "expected risk" pertaining to the PVI method was also factored into this study

[25]. This underscores the necessity of recognizing the inherent risks entailed by the PVI method prior to its application. Consequently, a judicious assessment weighing the potential benefits against the associated risks should guide the decision-making process when considering the adoption of the PVI method.

The utilization of the Pulmonary Vein Isolation (PVI) method holds a significant role in the comprehensive management of atrial fibrillation (AF). Central to this method is the isolation of the pulmonary veins, a strategy contributing to a reduction in AF risk [26]. Robust research substantiates the efficacy of PVI as a potent solution for AF, particularly when combined with catheter ablation (CA) compared to flutter ablation [25]. However, PVI comes with a range of potential risks, including complications like pericardial tamponade, stroke, pulmonary vein stenosis, bleeding events, and even mortality [26]. Therefore, an informed consideration of the risk-benefit equation becomes paramount in determining the suitability of PVI [27]. Strikingly, investigations have unveiled a potential link between PVI and elevated cancer incidence and mortality rates [28,29]. In-depth scrutiny reveals that adding ablation of complex fractionated atrial electrograms (CFAEs) to PVI confers no added benefit, indeed associated with an increased risk of stroke and death [23]. Furthermore, the incorporation of empirical superior vena cava isolation (SVCI) demonstrates no tangible benefits in terms of minimizing atrial arrhythmia risk post PVI [24]. Moreover, the advantages of PVI extend uniformly across different age groups [30], highlighted through research examining the prophylactic use of PVI to mitigate future AF risk in patients with atrial flutter (AFL), showcasing its similarity in effectiveness across varying age brackets [31]. Consequently, the integration of CFAE ablation into PVI has not demonstrated additional benefits [32], underscoring the critical need for an informed and nuanced approach to harnessing the potential of PVI in AF management.

3.5 AV Node Ablation and Pacemaker Implantation

AV node ablation and pacemaker implantation (AVNA) emerges as a viable long-term approach in the management of atrial fibrillation (AF). This intervention encompasses the deliberate disruption of the atrioventricular (AV) node alongside the insertion of a permanent pacemaker [33]. This strategic intervention

intentionally interrupts the AV node's role in coordinating electrical signals between the atria and ventricles. Subsequently, a pacemaker is introduced to sustain a steady heart rate. As part of managing AF, AV node ablation with permanent ventricular pacing stands as a logical recourse when pharmacological interventions fall short [34]. In this context, His bundle pacing (HBP) presents an appealing alternative to traditional right ventricular pacing, noted for its more physiological effects [34]. The safety and feasibility of HBP in patients undergoing AV node ablation are currently under investigation [34]. Notably, while the success rate of HBP in the setting of AV node ablation reaches 95%, instances like the dislodgment of a successfully implanted HBP lead during right-sided ablation underscore the significance of meticulous procedure execution [34].

The potential advantages of biventricular pacing hold promise, although their substantiation awaits further evidence [35]. AV node ablation is robust in controlling ventricular rate and mitigating symptoms [35]. However, the prolonged utilization of right ventricular pacing may potentially contribute to heart failure (HF) induction [35]. This risk amplifies when coupled with the advancement of underlying disease, often triggering HF due to the cumulative impact of permanent right ventricular pacing [35]. Notably, even patients with normal baseline cardiac function may be susceptible to HF following AV node ablation [35]. It is noteworthy that while all-cause mortality occurs in 26% of patients, and hospitalizations for HF in 20% [35], quality of life remains comparable to the control group at the end of the follow-up [35]. Despite these complexities, AV node ablation is aptly considered for those with severe adverse effects from rate-control drugs [35], often representing a last-resort solution for drug-resistant and poorly tolerated atrial fibrillation [36]. Importantly, the execution of AV node ablation mandates the insertion of a permanent pacemaker. For chronic atrial fibrillation, a VVIR pacemaker is typically chosen, while DDDR mode-switching devices become more appropriate for severely symptomatic episodes of paroxysmal atrial fibrillation [36]. In summation, AV node ablation and pacemaker implantation emerge as a potent therapeutic modality for managing atrial fibrillation and taming rapid ventricular rates.

In AV node ablation (AVNA), a procedure aimed at addressing specific heart arrhythmias, a catheter sheath is introduced into the heart to

access the atrioventricular (AV) node [34]. In cases where His Bundle pacing (HBP) is in place, added caution is essential when targeting the ablation site, given the potential for an acute rise in His capture threshold if ablation occurs in close proximity to the tip electrode [34]. A profound comprehension of the location of the HBP lead's tip and ring electrodes can serve as a valuable guide during ablation [34]. Depending on patient circumstances, the sequence of HBP lead implantation and AVNA can be adjusted [34]. Implanting the HBP lead ahead of AVNA is recommended, providing a radiographic landmark for subsequent ablation site identification [34]. While HBP's safety during AVNA is established, the possibility of dislodgment during the ablation procedure, as seen in one case, necessitates enhanced vigilance for patient safety [34]. Thus, meticulous execution remains pivotal to ensure the procedure's effectiveness and patient well-being.

Furthermore, it's crucial to acknowledge potential risks associated with AVNA, such as sudden death due to AV node disruption and pacemaker insertion [33]. Despite these considerations, research underscores the stability of left ventricular (LV) function and functional class in long-term follow-up [35]. Moreover, the need for a backup ventricular pacing lead is dictated by factors including high-voltage bipolar pacing (HBP) threshold exceeding 2V, unreliable RV sensing, or the presence of underlying left bundle branch block [34]. In this light, AVNA emerges as a potent and effective option for AF management [37]. Investigation into the long-term impact of AVNA also reveals reassuring results [38], with no significant disparity between the AVNA group and the control group observed after 6 months of follow-up [38]. This further supports AVNA's efficacy as a sustained AF treatment. Leveraging specific devices can enhance the efficiency of mapping and ablation procedures [39]. Notably, pre-emptively identifying patients prone to LV dyssynchrony before AVNA facilitates optimal treatment choices [40]. Additionally, insights into the hemodynamic implications of AVNA underscore the viability of employing a biventricular pacemaker device combined with a bipolar right ventricular lead and a unipolar lead [41]. Lastly, the swift execution of AV junction ablation and insertion of a DDDR pacemaker within 24 hours post-AVNA establishes this procedure as a tangible option for long-term AF management.

3.6 Cardiac Resynchronization Therapy (CRT)

Cardiac Resynchronization Therapy (CRT) stands as a significant approach in addressing heart failure and diverse medical conditions [42]. This technique involves the implantation of a specialized pacemaker device within the patient's chest, orchestrating synchronization between the left and right ventricles. The outcome is an enhanced overall heart function and the potential reduction of atrial fibrillation episodes. The application of CRT devices holds promise in the management of heart failure patients [42]. Nevertheless, substantial variations emerge concerning the demographics of patients, including the elderly, those with atrial fibrillation, or prior device implantation [42]. While the specific role of CRT in managing atrial fibrillation remains unelaborated in the provided text, its complexity is acknowledged. Typically employed in conjunction with medications, lifestyle adjustments, and other interventions, CRT extends its utility to conditions like heart block, tachycardia, and ventricular arrhythmias [42]. The implantation procedure employs pacemaker-like devices with electrodes placed on the chest, functioning by administering electrical impulses to reinstate normal heart rhythm. The procedure, adaptable to outpatient or hospital settings, establishes CRT as a secure and efficient approach to address atrial fibrillation and diverse cardiac ailments.

As an established option, cardiac resynchronization therapy (CRT) assumes significance for individuals contending with heart failure, compromised left ventricular (LV) function, and broad QRS complexes [43]. Evidenced in its capacity to curtail mortality rates and elevate life quality among congestive heart failure (CHF) patients, CRT manifests substantial merit [44]. Moreover, CRT exercises its influence in diminishing the vulnerability to sudden cardiac death linked to implantable cardioverter-defibrillator (ICD) usage [45]. The application of CRT also yields affirmative outcomes for those grappling with end-stage heart failure [46]. Notably, patients with left ventricular systolic dysfunction garner substantial benefit from CRT intervention [47]. Nevertheless, the absence of a conclusive biomarker to predict CRT response persists as an ongoing concern [48]. In addition to these, CRT extends its utility to individuals bearing dilated cardiomyopathy, as endorsed by the European Society of Cardiology (ESC) [49]. A case study spotlighting the benefits of CRT in a

patient navigating chronic atrial fibrillation and intraventricular conduction defect (IVCD) further underscores the diverse clinical advantages it brings [50]. Collectively, the multi-dimensional merits of CRT emerge as an effective avenue for managing atrial fibrillation and encompassing clinical exigencies.

While the potential risks and side effects associated with Cardiac Resynchronization Therapy (CRT) remain areas of active exploration [42], prevailing insights hint at nuanced dimensions. The therapeutic benefits of CRT might be offset by escalated peri-operative complication rates, particularly pertinent for patients with mild symptoms [42]. It's also noteworthy that life-extending defibrillator therapy correlates with an augmented heart failure risk [42]. Consequently, rigorous investigations are warranted to comprehensively delineate potential risks and side effects. Further dissection of CRT mechanisms and optimal applications for heart failure treatment is imperative. This deeper understanding enables healthcare practitioners to strike a balance, harnessing CRT to mitigate complications while optimizing its therapeutic impact.

3.7 Lifestyle Modifications for Managing Atrial Fibrillation

Atrial fibrillation (AF) management can be significantly influenced by certain lifestyle modifications that contribute to symptom reduction and improved overall outcomes. These changes encompass various aspects of cardiovascular health and have been investigated extensively [51]. Addressing modifiable risk factors through lifestyle adjustments offers a promising avenue for managing AF [51].

Recent evidence underscores the potential benefits of lifestyle modifications in AF management, with a specific focus on autonomic nervous system modulation [52]. These modifications exhibit the capacity to influence arrhythmia development and AF therapy by impacting autonomic tone [53,54]. Feasibility trials have probed the effects of autonomic modulation therapy, aiming to enhance AF management [55]. Alterations in lifestyle are believed to positively affect autonomic modulation, leading to a potential reduction in cardiovascular disease morbidity and mortality [56]. Notably, lifestyle modifications, including structured exercise and increased physical

activity, demonstrate the capacity to improve cardiac autonomic function [57]. This impact is particularly pronounced on heart rate and parasympathetic modulation [58,59]. Intriguingly, music intervention in tandem with lifestyle modifications has shown promise in promoting autonomic balance among individuals with prehypertension and hypertension [54]. The potential of lifestyle changes to improve cardiac autonomic health and mitigate transient increases in cardiac autonomic modulation is also suggested [59]. In light of these findings, adopting lifestyle modifications emerges as a prudent approach to AF management.

3.8 Autonomic Modulation Techniques

Autonomic modulation hinges on influencing the autonomic nervous system, often employing methodologies like music therapy. Research highlights its potential to reduce sympathetic activity and enhance parasympathetic activity, inducing physiological relaxation [59]. However, the specific techniques employed in this modulatory approach warrant further elucidation [59]. Music therapy, for instance, has been linked to alterations in heart rate variability (HRV), with some studies reporting elevated heart rate, while others note no change or a decrease [59]. Notably, techniques such as coordinated body and breath movements and deliberate slow movements are also employed for autonomic modulation [56].

Autonomic modulation strategies align with the evolving landscape of AF management [52]. Lifestyle modifications, fortified by evidence-based research, hold potential to mitigate cardiovascular diseases and enhance AF management outcomes [54]. The realm of interventions includes physical activity, dietary adjustments, and music-based strategies, aimed at augmenting cardiac autonomic function and controlling heart rate variability [58,59]. Although feasibility trials exploring lifestyle and autonomic modulation are somewhat limited, their exploration is pivotal [55]. These interventions can potentially foster cardiorespiratory fitness improvement and enhance AF management efficacy [57]. Further research remains essential to ascertain their broader implications [56]. Therefore, delving into lifestyle modifications and their impact on autonomic modulation marks a meaningful step in advancing AF management strategies [59].

Weight Management: Addressing weight through management is a pivotal factor in AF prevention and management [51]. Risk factors, including obesity, have a profound connection to AF development, and comprehensive risk factor management can significantly reduce symptoms and AF burden [51]. The relationship between body mass index (BMI) and AF incidence is robust, and lifestyle interventions that promote weight loss can result in considerable symptom improvement and enhanced quality of life [60]. Obesity's links to comorbidities like hypertension, diabetes, and sleep apnea further underline the significance of weight management in reducing AF occurrence [51]. Consequently, effective weight management strategies contribute to both AF prevention and management by tackling root causes and related complications.

Exercise: The role of exercise and lifestyle modifications in AF management has gained prominence [51]. The incorporation of lifestyle changes into AF management, as demonstrated by the Clinical Effectiveness of the Risk Factor Management Clinic in Atrial Fibrillation (CENT) study, holds considerable promise [51]. Exercise is pivotal in lifestyle modifications, offering benefits such as weight loss, improved cardiovascular fitness, symptom reduction, and enhanced quality of life [61]. The engagement of patients in self-initiated behavioral changes, including physical activity, yields positive outcomes in AF management [61]. Structured self-management programs, promoting components such as BMI control, tobacco cessation, moderation of alcohol intake, and regular exercise, have showcased effectiveness [52]. The multifaceted nature of cardiac rehabilitation programs further contributes to cardiovascular risk management and sustained weight loss [62]. Effective patient education, often facilitated through tailored health information packages, amplifies the impact of these lifestyle interventions [63]. Exercise and other lifestyle changes collectively stand as essential components of AF management, steering disease progression and optimizing patient outcomes [53,54].

Alcohol Reduction: Alcohol consumption's recommended level for AF individuals has garnered attention [51]. Integrating lifestyle changes and risk factor management interventions into AF care, as affirmed by the Risk Factor Management Clinic in Atrial Fibrillation (CENT) study, offers compelling benefits [51]. Lifestyle modifications, including

self-efficacy and behavior changes, have demonstrated their value in AF management [61]. Structured self-management programs have underscored their efficacy in sustained weight loss, requiring continued evaluation within dedicated risk factor management programs [52,55]. Specific interventions like alcohol reduction have exhibited promise in AF management, strengthening the case for effective self-management practices [53]. The role of patient education, delivered through comprehensive health information packages, cannot be overstated [63]. Meta-analyses underline the efficacy of catheter ablation of AF, particularly in individuals with obstructive sleep apnea, accentuating lifestyle's multifaceted influence [64]. In conclusion, adopting structured self-management programs and effective patient education to reduce alcohol consumption is a cornerstone of comprehensive AF management.

Obesity, Sleep, and AF Management: Modifiable risk factors like obesity, sleep apnea, and others hold the key to effective AF management [51]. Managing these factors comprehensively promises symptom reduction, successful ablations, and improved outcomes [51]. Evidence points to the impact of aggressive risk factor management, reinforcing the value of integrating lifestyle interventions into AF care [51]. Behavioral strategies targeting lifestyle adjustments, including regular physical activity, BMI control, tobacco cessation, and alcohol moderation, are central [56]. It's important to acknowledge that AF patients must navigate treatment choices, medication adherence, lifestyle shifts, wearable technology use, and emotional well-being to optimize quality of life [56]. In essence, lifestyle modifications constitute an impactful dimension in enhancing AF outcomes.

Limitations of Lifestyle Modifications: While lifestyle modifications hold promise in AF management, certain limitations warrant consideration [56]. The availability of comprehensive studies remains a challenge, with some research featuring small sample sizes and homogenous populations [56]. Evaluating the efficacy of lifestyle changes in isolation, without factoring risk management and medication, poses complexity [57]. However, combining risk factor management and lifestyle modification yields superior results in cardiovascular and diabetes-related complications [57]. Time constraints can impede effective patient communication about potential lifestyle

modifications [53]. While managing sleep apnea and other lifestyle factors can alleviate AF symptoms, lifestyle modifications alone may not offer a cure, and the limitations of existing medication options highlight the need for a comprehensive approach [65]. Furthermore, the predictive accuracy of stroke risk scores underscores the necessity for a holistic strategy that embraces medication, risk factor management, and lifestyle modifications [58]. Thus, the role of lifestyle modifications, while valuable, requires a balanced approach within a comprehensive treatment framework.

3.9 Treating Sleep Apnea and Sleep Disorders in Atrial Fibrillation

Obstructive sleep apnea (OSA) is prevalent among atrial fibrillation (AF) patients and is considered a contributing factor to the initiation and progression of AF [66]. Addressing sleep apnea offers a modifiable avenue for therapeutic intervention, with potential benefits for AF management [66]. Emerging evidence suggests that treating OSA can lead to improved AF control and potentially reduce AF recurrence rates [67]. Notably, OSA treatment prior to ablation has been linked to decreased AF recurrence [68]. In alignment with this notion, the 2016 European Society of Cardiology Guidelines emphasize the importance of evaluating AF patients for symptoms of OSA and vice versa [69]. The cornerstone of OSA treatment is continuous positive airway pressure (CPAP) therapy, which has demonstrated efficacy in both sleep apnea management and enhancing AF control [66]. Optimizing OSA treatment can enhance the outcomes of AF therapies by improving overall AF management [67]. Considering that OSA contributes to autonomic and metabolic disruptions and cardiovascular disorders, its treatment holds therapeutic implications for AF management [66]. However, while some international cardiologists advocate for OSA treatment in AF management, the relationship still lacks universal consensus [67]. Additional research is required to solidify the connection between OSA treatment and the efficacy of AF therapies [66].

The establishment of CPAP therapy's efficacy in AF management necessitates robust large-scale randomized clinical trials [70]. Such trials can also pave the way for identifying biomarkers that facilitate personalized OSA treatment plans [70]. Presently, CPAP's impact has been mainly explored in the context of reducing OSA-

associated morbidity and mortality [70]. While varied in results, these studies have indicated potential benefits in AF endpoints with CPAP treatment for OSA [67]. A survey of AF experts underscores the consensus that randomized controlled trials investigating OSA treatment in AF patients are essential [67]. This collective willingness to contribute underscores the potential for further evidence on the effectiveness of this intervention.

Evidence from expert surveys underscores the link between sleep-disordered breathing (SDB) and AF [71,72]. Specifically, obstructive sleep apnea (OSA) has been identified as a predictor for AF [72]. Positive airway pressure (PAP) therapy, notably continuous positive airway pressure (CPAP), is the mainstay of OSA treatment [70]. PAP therapy potentially mitigates AF burden and enhances AF treatment outcomes [73]. Thus, clinicians are encouraged to utilize OSA as a risk indicator for AF, closely monitoring both conditions and addressing OSA appropriately [68]. Additionally, weight loss and smoking cessation emerge as potential sleep apnea interventions [74], while CPAP therapy displays promise in arrhythmia prevention and AF management [75]. Exploring pharmacotherapy as a complementary approach to OSA management also warrants consideration [69]. The potential of OSA treatment as an AF management strategy remains promising, warranting further research [67].

Atrial fibrillation (AF) management encompasses various dimensions, including addressing risk factors and utilizing interventions such as anticoagulation, rhythm control, and rate control strategies [76]. Obstructive sleep apnea (OSA) is closely tied to AF risk [73][69]. Notably, recent evidence underscores the role of night-to-night variability in OSA severity as an independent AF risk factor [77]. For accurate assessment, identifying severe OSA (AHI > 40) is crucial [78]. Advanced tools, such as the DREAM algorithm, aid in severe sleep apnea identification [79]. The goal of OSA management in AF lies in minimizing AF recurrence, with CPAP therapy serving as an adjunct for arrhythmia prevention [74]. Studies emphasize that severe OSA significantly heightens AF risk [75], emphasizing the importance of CPAP therapy for moderate to severe OSA cases [80]. Notably, CPAP treatment is covered by the Canadian Assistive Devices Program [77]. It's vital to recognize that traditional modifiable ASCVD risk factors should concurrently be managed alongside OSA [76].

While CPAP therapy's efficacy stands evident in sleep apnea management [73], limitations warrant consideration [69]. CPAP access is restricted to the Assistive Devices Program [77], and the long-term implications of CPAP therapy on AF recurrence remain inconclusive [76]. Furthermore, the DREAM algorithm [79] specifically detects severe sleep apnea [78], potentially overlooking mild to moderate severity cases. Moreover, the risk gradient associated with obstructive sleep apnea [75] spans a range of AHI values, from 5 to 40, representing mild to moderate OSA [74], and exceeding 40, indicating severe OSA. Traditional medical and invasive measures are insufficient to address OSA [80]. In light of this, the ultimate objective of sleep apnea management in AF is minimizing AF recurrence [81], while enhancing the patient's well-being [76]. However, research gaps persist, necessitating a deeper exploration of CPAP therapy's safety and efficacy in long-term AF management [78][76].

Gold-standard randomized clinical trials play a pivotal role in treatment efficacy assessment [73]. This importance amplifies in the context of AF, a condition with critical implications. Biomarker identification for personalized OSA treatment plans is essential [81]. A notable percentage of cardiologists emphasize the necessity of randomized controlled trials for OSA treatment in AF patients [77]. This eagerness to contribute underscores the potential for substantiating the effectiveness of this approach. Understanding the pathophysiological influence of night-to-night variability in OSA severity on AF risk is a critical research avenue [79]. While CPAP remains a mainstay [70], personalized treatment refinement holds promise. The well-documented link between OSA and AF mandates vigilant monitoring and tailored interventions [68]. Therefore, early identification and effective management of severe sleep apnea are essential. This approach stands to mitigate risks associated with OSA and curtail the incidence of atrial fibrillation.

3.10 Ablation of Non-Pulmonary Vein Triggers in Atrial Fibrillation Management

Beyond the pulmonary veins, the heart harbors regions capable of generating abnormal electrical signals that contribute to atrial fibrillation (AF). The ablation of these non-pulmonary vein (NPV) triggers offers a promising avenue for preventing AF recurrence. Non-PV triggers have garnered

attention for their role in AF pathogenesis, with recent studies emphasizing their significance in AF persistence [82]. Ablating these triggers holds potential for managing recurrent or refractory cases of AF [82][83]. These triggers tend to originate from specific sites, including the left atrial posterior wall, superior vena cava, coronary sinus, interatrial septum, and crest terminalis [83]. Effective mapping techniques involving multielectrode catheters placed strategically in the right and left atrium facilitate quick localization of these triggers [83]. Ablation strategies span focal ablation to comprehensive isolation, tailored to the trigger's origin [83]. Despite their potential to contribute to arrhythmia relapse, the efficacy of NPV trigger ablation in AF management remains a topic of debate [84]. Notably, research suggests that patients with a heightened prevalence of NPV triggers could stand to benefit more from this approach [83]. Prioritizing these extra-pulmonary sites for ablation during the initial procedure is a prudent strategy [84]. The likelihood of arrhythmia recurrence due to NPV triggers is elevated, and changes in atrial substrate dynamics may reduce pulmonary vein (PV) trigger-induced AF [84]. Animal studies point to delayed afterdepolarization-induced triggered activity as a mechanism underlying atrial tachyarrhythmias [84]. NPV sites with preserved rapid conduction retain the potential to initiate ectopic beats, instigating AF [84]. Collectively, existing evidence underscores the potential of NPV trigger ablation as an effective strategy in AF management [84].

While ablation techniques targeting localized re-entrant activity have been explored, their efficacy remains uncertain [84]. However, the associated risks were not explicitly addressed in the study [84]. Additionally, conflicting results from small, non-randomized studies with suboptimal mapping methods contribute to the uncertainty [84]. Further, the long-term outcome data may be affected by the oversight of asymptomatic AF recurrence in follow-up approaches [82]. The possible non-inducibility or limited reproducibility during electrophysiological studies could result in true NPV triggers being overlooked [82]. Hence, triggers induced in electrophysiological studies may not align with actual clinical triggers [82]. Moreover, left ventricular ablation documented in endocardial mapping might not capture all atrial scarring/fibrosis [82]. The study's underpowered design stemming from a small sample size is an additional limitation [82]. The use of balloon-based catheters for cryoablation might have resulted in incomplete lesions, potentially

contributing to a lower incidence of de novo arrhythmias [83]. Furthermore, the effectiveness of cryoablation in targeting focal sites or small structures is constrained [83]. The durability of NPV trigger ablation poses another challenge [83]. Lastly, surgical ablation, while invasive, is limited by intraoperative mapping techniques [83].

The ablation of NPV triggers has gained prominence within the landscape of AF ablation [83]. This stems from the imperative of eliminating all possible triggers while minimizing ablation extent to achieve sustained efficacy [85]. Clinical investigations underscore the critical role of NPV trigger elimination, either through focal ablation or arrhythmogenic area isolation, in enhancing arrhythmia-free survival rates [86]. A 2020 study notably favored the addition of NPV trigger-targeted ablation over PV trigger-targeted ablation alone for paroxysmal AF patients [87]. Another study suggested the superiority of NPV trigger ablation over PV isolation in paroxysmal AF patients with left ventricular systolic dysfunction (LVSD) after a single ablation [88]. Since the discovery of pulmonary vein triggers in 1998 [89], catheter-based AF ablation techniques have continued evolving. A 2020 observational study scrutinizing the long-term outcomes of catheter ablation in patients with AF and NPV triggers concluded an arrhythmia-free survival rate of 81%, outperforming the 8% rate without NPV trigger ablation [84]. Complete eradication of AF inducibility from target sites was pursued throughout the ablation process, with additional ablation directed at documented NPV triggers [90]. Likewise, another study delved into the attributes and prolonged outcomes of catheter ablation among long-standing persistent AF patients with NPV triggers, affirming the procedure's positive impact [91]. Collectively, the mounting evidence suggests NPV trigger ablation's efficacy, positioning it as a compelling option in AF management [84].

3.11 Autonomic Modulation in Atrial Fibrillation Management

Autonomic modulation presents a promising therapeutic avenue for managing cardiac arrhythmias, notably atrial fibrillation (AF) [92]. By manipulating the autonomic nervous system, this approach seeks to modify the electrophysiological characteristics of atrial tissue, enhancing the efficacy of ablation therapies [92]. The strategy leverages the neural tissue's plasticity to induce beneficial neural remodeling [92]. Various forms of autonomic

modulation encompass vagus nerve stimulation (VNS), tragus stimulation, renal denervation, baroreceptor activation therapy, and cardiac sympathetic denervation [92]. Early trials, both preclinical and clinical, showcase the potential of autonomic modulation therapies in arrhythmia management [92]. To effectively employ autonomic modulation in AF management, it is crucial to optimize stimulation parameters and select patients based on appropriate biomarkers [92]. Heart rate variability, skin sympathetic nerve activity, and alternans serve as surrogate markers and predictors of treatment efficacy [92]. Notably, recent research highlights that a 3-minute VNS application can mitigate arrhythmia susceptibility [93]. Additionally, burst stimulation of mediastinal nerves, focusing on convergence neurons, reveals promise in transiently inducing AF [93]. By enhancing activity in afferent, efferent, and convergent neurons, burst stimulation of mediastinal nerves disrupts synchrony between these neuron types [93]. Perturbations in autonomic inputs to the intracardiac nervous system (ICNS) are linked to AF, with pre-emptive VNS attenuating the evoked ICNS neural response to mediastinal nerve stimulation, primarily targeting convergent neurons [93]. Autonomic modulation entails complex interactions between ganglionated plexi and higher centers, orchestrating regional cardiac function modulation [93]. Although interactions span multiple levels, the ICNS serves as the central cardiac control pathway [93]. Sympathetic and parasympathetic efferent fibers project to the ICNS, including left cardiac neurons (LCNs), with postganglionic sympathetic fibers also connecting directly to the myocardium [93]. Right atrial ganglionated plexus (RAGP) significantly influences parasympathetic input to the right atrium [93]. Ablating the RAGP results in near-total bradycardia elimination induced by vagal nerve stimulation [93]. Vagal nerve stimulation, an element of autonomic modulation, acts on AF management by inducing bradycardia and slowing atrioventricular node conduction through efferent activation of the Vagus nerve [93]. Furthermore, low-level current primarily targeting afferent pathways induces a tachycardia abolished by Vagus nerve transection [93], reinforcing the functional significance of neural pathways.

The effectiveness of autonomic modulation in arrhythmia management is underscored by the augmentation of cardiac vagal activity [94]. This property enhances the utility of vagal stimulation in reducing atrial fibrillation and ventricular

tachycardia risks [92]. Additionally, research indicates that left-sided vagal nerve stimulation is more potent in inducing atrial fibrillation compared to its right-sided counterpart, although the effects of mediastinal nerve stimulation are less pronounced [93]. Moreover, the intricate interplay between the autonomic nervous system and arrhythmia emergence highlights its pivotal role in initiating and sustaining atrial fibrillation [95]. Notably, the cardiac autonomic nerve system's modulation can influence atrial fibrillation onset and duration [96]. Collectively, these insights reinforce the effectiveness of autonomic modulation as a plausible therapeutic target for atrial fibrillation, although due consideration of associated risks is imperative, given its potential to engender unpredictable heart effects and serious complications.

Autonomic modulation stands apart from alternative atrial fibrillation treatments by centering on the autonomic nervous system's role in driving and perpetuating cardiac arrhythmias, particularly atrial fibrillation [92,94]. Experimental models, such as vagal activation, offer insights into neural mechanisms and the impact of neuromodulation, evident in its ability to limit infarct size and protect against ventricular arrhythmias during myocardial infarction [97]. These models facilitate a deeper understanding of neural mechanisms and the effects of autonomic modulation [98]. Moreover, the established linkage between the autonomic nervous system, arrhythmia development, and atrial fibrillation therapy underscores autonomic modulation's significance [95]. Ultimately, autonomic modulation distinguishes itself from other AF treatments through its focus on enhancing autonomic tone to induce neural remodeling for therapeutic gains.

3.12 Left Atrial Appendage Closure (LAAC) in Atrial Fibrillation Management

Left Atrial Appendage Closure (LAAC) stands as an effective approach for addressing atrial fibrillation (AF) and managing the associated risks. Research establishes that the left atrial appendage is the primary source of thrombus formation in approximately 90% of AF patients [99]. LAAC offers a viable alternative to oral anticoagulant therapy (OAT) for individuals at risk of bleeding complications [100]. This procedure entails the insertion of a WATCHMAN™ device into the left atrial appendage (LAA), effectively reducing both

stroke and bleeding risks [101]. Furthermore, LAAC can be strategically combined with catheter ablation (CA) to provide a comprehensive AF treatment [102]. Particularly advantageous for patients with OAT contraindications or primary hemostasis disorders, LAAC offers a solution that can be managed through appropriate plasmatic control [101]. Medium-term follow-up data substantiate the safety and efficacy of LAAC, demonstrating cumulative benefits over warfarin concerning major bleeding, stroke, and mortality [100]. Effective implementation requires a multidisciplinary approach, ensuring proper assessment, management, and follow-up [101]. Although OAT remains superior in stroke prevention, LAAC emerges as an effective alternative for those unable to tolerate conventional medications [100].

LAAC, employing the Watchman device, emerges as a cost-effective strategy for reducing stroke risk in patients with non-valvular AF who are unable to use warfarin [99]. A comprehensive study supported by the American Heart Association underscores the financial benefits of LAAC with the Watchman device in this patient group [99]. Furthermore, this combination of AF catheter ablation (AFCA) and percutaneous LAAC has the potential to decrease stroke incidence and alleviate AF symptoms concurrently, streamlining management [103]. In addition to stroke risk reduction, LAAC also significantly curbs bleeding risks [101]. Long-term follow-up data illustrate a notable decline in stroke and bleeding rates, bolstering LAAC's efficacy [102]. Despite AF recurrence in more than half of patients, the value of LAAC persists [102]. The successful combination of CA and LAAC validates its feasibility, safety, and positive outcomes [102]. Notably, LAAC surpasses alternatives like aspirin and apixaban in terms of effectiveness and cost-efficiency [99]. Projections highlight LAAC's cost-effectiveness over a decade for patients with warfarin contraindications [99]. The procedure emerges as a practical alternative to OACs for those who cannot tolerate them [103]. Effective LAAC patient selection and management necessitate a collaborative, multidisciplinary approach [103]. The integration of AFCA and percutaneous LAAC in a single session emerges as a viable approach for managing symptomatic, drug-refractory AF, high stroke risk, and strict or relative OAC contraindications [103]. Proficiency in both AF ablation and LAAC is crucial for operators, emphasizing the specialized nature of

the procedure [103]. Collectively, LAAC underscores its potential as an integral AF management strategy [103].

However, it is imperative to note that the probability of bleeding events, as drawn from studies like ACTIVE A and ACTIVE W [99], aligns closely with concomitant drug therapy. These studies, although valuable, do not provide long-term insights into bleeding outcomes post-LAAC [99]. The investigation involved the application of the Watchman device in non-valvular AF patients with absolute warfarin contraindications [99]. Results indicate that the bleeding event probabilities associated with LAAC mirror those linked to concomitant drug therapy [99]. This finding reinforces LAAC's potential as a valuable solution for stroke risk reduction and its cost-effective stance compared to alternatives such as aspirin and apixaban. Additionally, this research emphasizes LAAC's capacity to deliver safe and effective anticoagulation in cases where OACs are contraindicated.

4. CONCLUSION

In conclusion, non-pharmacologic management approaches offer valuable strategies for the effective control and treatment of atrial fibrillation. Techniques such as catheter ablation, autonomic modulation, left atrial appendage closure, and ablation of non-pulmonary vein triggers have demonstrated their potential to mitigate the risks associated with atrial fibrillation and improve patient outcomes. These interventions provide alternative options for patients who may not respond well to pharmacological therapies or who have contraindications to certain medications. With further research and advancements in these non-pharmacologic approaches, a more comprehensive and tailored approach to managing atrial fibrillation can be achieved, enhancing the quality of life for individuals affected by this cardiac arrhythmia. In the management of Atrial fibrillation, choice between rhythm and rate control, lifestyle modifications, and patient adherence to treatment plans are critical factors influencing outcomes are factors to consider. Emerging therapies offer promise, but timely diagnosis, individualized care, and ongoing monitoring remain essential to improving AF patients' overall prognosis.

5. STUDY LIMITATION

While the preceding discussions provide insights into various aspects of atrial fibrillation (AF)

management strategies, it is essential to acknowledge certain limitations inherent to the presented content. The provided information offers a broad overview of different AF management approaches. Due to the broad nature of atrial fibrillation, a concise approach of discussion was employed, thus, the depth of coverage for each strategy might be limited, and detailed nuances, potential complications, and evolving research may not be fully addressed. Also, AF management is highly individualized and depends on various factors, including patient preferences, comorbidities, age, and treatment response. The presented strategies and studies might not encompass the full spectrum of individual patient variation and considerations.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

DATA AVAILABILITY

The data used in this study was from published literatures that are publicly available in various data bases.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Nattel S. New ideas about atrial fibrillation 50 years on. (n.d.) Retrieved August 22. 2023415219.
2. Cox JL, Canavan TE, Schuessler, RB, et al.: The surgical treatment of atrial fibrillation: II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. *The Journal of Thoracic and Cardiovascular Surgery*. 1991; 101:406-426. DOI:10.1016/S0022-5223(19)36723-6
3. Lip G Tse H. Management of atrial fibrillation. *The Lancet*. 2007;370:604-618. DOI:10.1016/S0140-6736(07)61300-2
4. Connolly S, Laupacis A, Gent M, RobertsR, Cairns, JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study.. *Journal of the American College of Cardiology*. 1991;18:349-355. DOI:10.1016/0735-1097(91)90585-W

5. Wakili R, Voigt N, Kääh S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest.* 2011;121(8):2955-68.
DOI: 10.1172/JCI46315
6. Nattel S, Burstein B, Dobrev. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circulation: Arrhythmia.* 2008;1:62-73.
DOI:10.1161/CIRCEP.107.754564
7. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S, Epidemiology of atrial fibrillation: European perspective. 2014;213:220.
DOI:10.2147/CLEP.S47385
8. Leitz P, Stebel LM, Andresen C, Ellermann C, Güner F, Reinke F, Kochhäuser S, Frommeyer G, Köbe J, Wasmer K, Lange PS, Orwat S, Eckardt L, Dechering DG. Quantifying left atrial size in the context of atrial fibrillation ablation: Which echocardiographic method correlates to outcome of pulmonary venous isolation? *J Pers Med.* 2021;11(9):913.
DOI: 10.3390/jpm11090913
9. Lip GY, Beevers, DG. ABC of atrial fibrillation: history, epidemiology, and importance of atrial fibrillation. *Bmj.* 1995;311:13-61.
DOI:10.1136/bmj.311.7016.1361
10. Pritchett EL. Management of atrial fibrillation. *New England Journal of Medicine.* 1992;326:1264-1271.
DOI:10.1056/NEJM199205073261906
11. Bianconi L, Mennuni M, Lukic V, Castr A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. *Journal of the American College of Cardiology.* 1996;28:700-706.
DOI:10.1016/0735-1097(96)00230-6
12. Crijns HJGM, Van Gelder IC, Lie KI. Benefits and risks of antiarrhythmic drug therapy after DC electrical cardioversion of atrial fibrillation or flutter. *European Heart Journal.* 1994;15:17-21.
DOI:10.1093/eurheartj/15.suppl_A.17
13. Um KJ, McIntyre WF, Healey JS et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: A systematic review and meta-analysis. *EP Europace.* 2019;21:856-863.
DOI:10.1093/europace/euy310
14. de Paola A, Figueiredo E, Sesso R, Veloso HH, Nascimento LOT. Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation. *International Journal of Cardiology.* 2003;88:157-166.
DOI:10.1016/S0167-5273(02)00380-7
15. Gentile F, Elhendy A, Khandheria BK. Safety of electrical cardioversion in patients with atrial fibrillation. In. *Mayo Clinic Proceedings.* 2002;77:897-904.
DOI:10.4065/77.9.897
16. Själander S, Svensson PJ, Friberg L. Atrial fibrillation patients with CHA2DS2-VASc > 1 benefit from oral anticoagulation prior to cardioversion. *International Journal of Cardiology.* 2016;215:360-363.
DOI:10.1016/j.ijcard.2016.04.031
17. Haegeli LM, Calkins H, Catheter ablation of atrial fibrillation: An update. *European Heart Journal.* 2014;35:2454-2459.
DOI:10.1093/eurheartj/ehu291
18. Je HG, Shuman DJ, Ad N. A systematic review of minimally invasive surgical treatment for atrial fibrillation: A comparison of the Cox-Maze procedure, beating-heart epicardial ablation, and the hybrid procedure on safety and efficacy. *European Journal of Cardio-Thoracic Surgery.* 2015; 48:531-541.
DOI:10.1093/ejcts/ezu536
19. Lall SC, Melby SJ, Voeller, RK, et al. The effect of ablation technology on surgical outcomes after the Coxmaze procedure: A propensity analysis. *The Journal of Thoracic and Cardiovascular Surgery.* 2007;133:389- 396.
DOI:10.1016/j.jtcvs.2006.10.009
20. Melby SJ, Zierer A, Bailey MS, Cox JL, Lawton JS, Munfakh N, Damiano Jr. RJ. A new era in the surgical treatment of atrial fibrillation: The impact of ablation technology and lesion set on procedural efficacy. *Annals of Surgery.* 2006;244:583.
DOI:10.1097/01.sla.0000237654.00841.26
21. Stulak JM, Sundt III, TM, Dearani JA, Daly RC, Orsulak TA, Schaff HV. Ten-year experience with the Cox-maze procedure for atrial fibrillation: How do we define success?. *The Annals of Thoracic Surgery.* 2006;83:1319-1324.
DOI:10.1016/j.athoracsur.2006.11.007
22. Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. *The Annals of Thoracic Surgery.* 1993;56:814-824.
DOI:10.1016/0003-4975(93)90338-I

23. Hayward, RM, Upadhyay, GA, Mela, T, et al. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and non-paroxysmal atrial fibrillation: A meta-analysis. *Heart Rhythm*. 2011;8:994-1000. DOI:10.1016/j.hrthm.2011.02.033
24. Da Costa A, Levallois M, Romeyer-Bouchard C, Bisch L, Gate-Martinet A, Isaaz K. Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: A prospective randomized study. *Archives of Cardiovascular Diseases*. 2015;108:163-171. DOI:10.1016/j.acvd.2014.10.005
25. Gula LJ, Skanes AC, Klein GJ, et al. Atrial flutter and atrial fibrillation ablation-sequential or combined? A cost-benefit and risk analysis of primary prevention pulmonary vein ablation. *Heart Rhythm*. 2016;13:1441- 1448. DOI:10.1016/j.hrthm.2016.02.018
26. Calvo N, Bisbal F, Guiu, E, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. *International Journal of Cardiology*. 2013;168:4093-4097. DOI:10.1016/j.ijcard.2013.07.017
27. Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. *Journal of Cardiovascular Electrophysiology*. 2009; 20:22-28. DOI:10.1111/j.1540-8167.2008.01275
28. Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. *Journal of the American College of Cardiology*. 2007;50:234-242. DOI:10.1016/j.jacc.2007.03.040
29. Li WJ, Bai, YY, Zhang, HY, et al. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation: A meta-analysis. *Circulation: Arrhythmia and Electrophysiology*. 2011;4:143-148. DOI:10.1161/circep.110.958405
30. Bhargava M, Marrouche N, Martin DO, Schweikert RA, Saliba W, Saad EB, Natale A. Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled-tip ablation catheter: A retrospective analysis. *Journal of Cardiovascular Electrophysiology*. 2004; 15:8-13. DOI:10.1046/j.1540-8167.2004.03266.x
31. Mohanty S, Natale A, Mohanty P, et al. Pulmonary vein isolation to reduce future risk of atrial fibrillation in patients undergoing typical flutter ablation: Results from a randomized pilot study (REDUCE). 2015;26:819-825. DOI:10.1111/jce.12688
32. Nademanee, K, Amnueypol, M, Lee, F, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. *Heart Rhythm*. 2015;12:44-51. DOI:10.1016/j.hrthm.2014.09.049
33. Wang RX, Lee HC, Hodge DO, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. *Heart Rhythm*. 2013;10:696- 701. DOI:10.1016/j.hrthm.2013.01.021
34. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. *EP Europace*. 2017;19:10-16. DOI:10.1093/europace/eux263
35. Tan ES, Rienstra M, Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van Gelder IC. Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. *Europace*; 2018. DOI:10.412-418. 10.1093/europace/eun020
36. Touboul P. Atrioventricular nodal ablation and pacemaker implantation in patients with atrial fibrillation. *The American Journal of Cardiology*. 1999;83:241-245. DOI:10.1016/S0002-9149(98)01036-4
37. Ozcan C, Jahangir A, Friedman PA, et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. 2003;92:33-37. DOI:10.1016/S0002-9149(03)00460-0
38. Natale, A, Zimerman, L, Tomassoni, G, et al. : AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: Effect on quality of life and

- exercise performance. *Pacing and Clinical Electrophysiology*. 1999;22:1634-1639. DOI:10.1111/j.1540-8159.1999.tb00383.x
39. Ruiz-Granell R, Morell-Cabedo S, Ferrero-de-Loma A, García-Civera R. Atrioventricular node ablation and permanent ventricular pacemaker implantation without fluoroscopy: Use of an electroanatomic navigation system. *Journal of Cardiovascular Electrophysiology*. 2005;16:793-795. DOI:10.1046/j.1540-8167.2005.40774.x
40. Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. *Journal of the American College of Cardiology*. 2006;48:1642-1648. DOI:10.1016/j.jacc.2006.05.072
41. Doshi RN, Daoud EG, Fellows C et al. Left Ventricular-based cardiac stimulation post AV nodal ablation evaluation (The PAVE Study). *Journal of Cardiovascular Electrophysiology*. 2005;16:1160-1165. DOI:10.1111/j.1540-8167.2005.50062.x
42. Dickstein K, Bogale N, Priori S et al. The European cardiac resynchronization therapy survey. *European Heart Journal*. 2009;30:2450-2460. DOI:10.1093/eurheartj/ehp359
43. Leyva F, Nisam S, Auricchio A. Years of cardiac resynchronization therapy. *JACC*. 2014;64:1047-58. DOI:10.1016/j.jacc.2014.06.1178
44. Linde C, Ellenbogen K, McAlister, FA. Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations. *Heart Rhythm*. 2012;9:3-13. DOI:10.1016/j.hrthm.2012.04.026
45. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart failure events. *New England Journal of Medicine*. 2009;361:1329-1338. DOI:10.1056/nejmoa0906431
46. Bleeker, GB, Bax, JJ, Fung, JWH, et al.: Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. *The American Journal of Cardiology*. 2006;97:260-263. DOI:10.1016/j.amjcard.2005.08.030
47. Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *New England Journal of Medicine*. 2010;363:2385-2395. DOI:10.1056/nejmoa1009540
48. YU CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy—Current and future perspectives. *Journal of Cardiovascular Electrophysiology*. 2005;16:1117-1124. DOI:10.1111/j.1540-8167.2005.40829.x
49. Castellant P, Fatemi M, Bertault-Valls V, Etienne Y, Blan JJ. Cardiac resynchronization therapy: “nonresponders” and “hyperresponders”. *Heart Rhythm*. 2008;5:193-197. DOI:10.1016/j.hrthm.2007.09.023
50. Vijayaraman P, Herweg B, Ellenbogen KA, Gajek J. His-optimized cardiac resynchronization therapy to maximize electrical resynchronization: A feasibility study. *Circulation: Arrhythmia and Electrophysiology*. 2019;12:006934. DOI:10.1161/CIRCEP.118.006934
51. Middeldorp ME, Ariyaratnam J, Lau D, Sanders P.; Lifestyle modifications for treatment of atrial fibrillation. *Heart*. 2020;106:325-332. DOI:10.1136/heartjnl-2019-315327
52. Benjamin EJ, Al-Khatib SM, Desvigne-Nickens P, et al.: Research priorities in the secondary prevention of atrial fibrillation: A National Heart, Lung, and Blood Institute virtual workshop report; 2021 (ed). DOI:10.1161/JAHA.121.021566
53. Griffin JM, Stuart-Mullen LG, Schmidt MM, et al.: Preparation for and implementation of shared medical appointments to improve self-management, knowledge, and care quality among patients with atrial fibrillation. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*. 2018;2:218-225. DOI:10.1016/j.mayocpiqo.2018.06.003
54. Qvist I, Lane DA, Risom SS, et al.: Implementation of patient education for patients with atrial fibrillation: Nationwide cross-sectional survey and one-year follow-up. *European Journal of Cardiovascular Nursing*, zvad066; 2023. DOI:10.1093/eurjcn/zvad066
55. Lau DH, Nattel S, Kalman JM, Sanders P.; Modifiable risk factors and atrial fibrillation. *Circulation*. 2017;136:583-596.
56. Sears SF, Anthony S, Harrell R, et al.: Managing atrial fibrillation: The intersection of cardiology, health psychology, and the patient experience. *Health Psychology*. 2022;41:792. DOI:10.1037/hea0001135

57. Lee SR, Ahn HJ, Choi EK, et al.: Improved prognosis with integrated care management including early rhythm control and healthy lifestyle modification in patients with concurrent atrial fibrillation and diabetes mellitus: A nationwide cohort study. *Cardiovascular Diabetology*. 2023; 22:18.
DOI:10.1186/s12933-023-01749-z
58. Chao TF, Joung B, Takahashi Y, et al.: Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: Executive summary. *Thrombosis and hemostasis*. 2021;122:020-047.
DOI:10.1055/s-0041-1739411
59. Weber C, Hung J, Hickling S, et al.: Incidence, predictors and mortality risk of new heart failure in patients hospitalized with atrial fibrillation. *Heart*. 2021;107:1320-1326.
DOI:10.1136/heartjnl-2020-318648
60. Larsen RT, Gottlieb CR, Wood KA, Risom SS.: Lifestyle interventions after ablation for atrial fibrillation: A systematic review. *European Journal of Cardiovascular Nursing*. 2020;19: 564-579.
DOI:10.1177/1474515120919388
61. Mehta NK, Strickling J, Mark E, et al. : Beyond cardioversion, ablation and pharmacotherapies: Risk factors, lifestyle change and behavioral counseling strategies in the prevention and treatment of atrial fibrillation. 2021;66:2-9.
DOI:10.1016/j.pcad.2021.05.002
62. Rosman L, Armbruster T, Kyazimzade S, et al. : Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. *Pacing and Clinical Electrophysiology*. 2021;44:451-461.
DOI:10.1111/pace.14188
63. Woo BF, Bulto LN, Hendriks JM, Lim TW, Tam WW.: The information needs of patients with atrial fibrillation: A scoping review. *Journal of Clinical Nursing*. 2023;32:1521-1533.
DOI:10.1111/jocn.15993
64. Yang L, Chung MK.: Lifestyle changes in atrial fibrillation management and intervention. *Journal of Cardiovascular Electrophysiology*; 2023.
DOI:10.1111/jce.15803
65. Bashir MU, Bhagra A, Kapa S, McLeod CJ.: Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation. *Reviews in cardiovascular medicine*. 2019;20:129-137.
DOI:10.31083/j.rcm.2019.03.517
66. Goyal SK, Sharma A.: Atrial fibrillation in obstructive sleep apnea . *World journal of cardiology*. 2023;5:157.
DOI:10.4330/wjc.v5.i6.157
67. Faulx MD, Mehra R, Geovanini GR, et al. : Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists. *IJC Heart & Vasculature*. 2022;42:101085.
DOI:10.1016/j.ijcha.2022.101085
68. Loomba RS, Arora R.: Obstructive sleep apnea and atrial fibrillation: A call for increased awareness and effective management. *American Journal of Therapeutics*. 2012;19:21-24.
DOI:10.1097/MJT.0b013e3181e70c49
69. Desteghe L, Hendriks JM, McEvoy RD, et al.: The why, when and how to test for obstructive sleep apnea in patients with atrial fibrillation. *Clinical Research in Cardiology*. 2018;107:617-631.
DOI:10.1007/s00392-018-1248-9
70. Ayas NT, Taylor CM, Laher I.: Cardiovascular consequences of obstructive sleep apnea . *Current Opinion in Cardiology*. 2016;31:599-605.
DOI:10.1097/HCO.0000000000000329
71. Linz D, Baumert M, Desteghe L, et al.: Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. *IJC Heart & Vasculature*. 2019;24:100424.
DOI:10.1016/j.ijcha.2019.100424
72. Iwasaki YK.: Mechanism and management of atrial fibrillation in the patients with obstructive sleep apnea. *Journal of Arrhythmia*. 2022; 38:974-980.
DOI:10.1002/joa3.12784
73. Fein AS, Shvilkin A, Shah D, et al.: Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. *Journal of the American College of Cardiology*. 2013;62:300-305.
DOI:10.1016/j.jacc.2013.03.052
74. Linz D, McEvoy RD, Cowie MR, et al.: Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: A review. *JAMA cardiology*. 2018;3:532-540.
DOI:10.1001/jamacardio.2018.0095

75. Gami AS, Somers VK : Implications of obstructive sleep apnea for atrial fibrillation and sudden cardiac death. *Journal of cardiovascular electrophysiology*. 2008;19: 997-1003.
DOI:10.1111/j.1540-8167.2008.01136.x
76. Miller JD, Aronis KN, Chrispin J, et al.: Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. *Journal of the American College of Cardiology*. 2015;66:2899-2906.
DOI:10.1016/j.jacc.2015.10.047
77. Kendzerska T, Gershon AS, Atzema C, et al.: Sleep apnea increases the risk of new hospitalized atrial fibrillation: A historical cohort study. *Chest*. 2018;154:1330-1339.
DOI:10.1016/j.chest.2018.08.1075
78. Gami AS, Hodge DO, Herges RM, et al.: Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *Journal of the American College of Cardiology*. 2007;49:565-571.
DOI:10.1016/j.jacc.2006.08.060
79. Linz D, Brooks AG, Elliott AD, et al.: Variability of sleep apnea severity and risk of atrial fibrillation: The VARIOS-AF study. *JACC: Clinical Electrophysiology*. 2019;5:692-701.
DOI:10.1016/j.jacep.2019.03.005
80. Shukla A, Aizer A, Holmes D, et al.: Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: A meta-analysis. *JACC: Clinical Electrophysiology*. 2015;1:41-51.
DOI:10.1016/j.jacep.2015.02.014
81. Marulanda-Londono E, Chaturvedi S,: The interplay between obstructive sleep apnea and atrial fibrillation. *Frontiers in Neurology*. 2017;8:668.
DOI:10.3389/fneur.2017.00668/full
82. Kawai S, Mukai Y, Inoue S, et al.: Non-pulmonary vein triggers of atrial fibrillation are likely to arise from low-voltage areas in the left atrium. *Scientific reports*. 2019;9:12271-41598.
83. Gianni C, Mohanty S, Trivedi C, Di Biase L, Natale A: Novel concepts and approaches in ablation of atrial fibrillation: The role of non-pulmonary vein triggers. *Ep Europace*. 2018;20:1566-1576.
DOI:10.1093/europace/euy034
84. Della Rocca DG, Mohanty S, Trivedi C, Di Biase L, Natale A,: Percutaneous treatment of non-paroxysmal atrial fibrillation: A paradigm shift from pulmonary vein to non-pulmonary vein trigger ablation?. *Arrhythmia & Electrophysiology Review*. 2018;7:256.
DOI:10.15420/aer.2018.56.2
85. Santangeli P, Marchlinski FE,: Techniques for the provocation, localization, and ablation of nonpulmonary vein triggers for atrial fibrillation. *Heart rhythm*. 2017;14:1087-1096.
DOI:10.1016/j.hrthm.2017.02.030
86. Della Rocca DG, Tarantino N, Trivedi C, et al.: Non-pulmonary vein triggers in nonparoxysmal atrial fibrillation: Implications of pathophysiology for catheter ablation. *Journal of cardiovascular electrophysiology*. 2020;31:2154-2167.
DOI:10.1111/jce.14638
87. Fukunaga M, Nagashima M, Korai K, et al.: Clinical impact of eliminating nonpulmonary vein triggers of atrial fibrillation and nonpulmonary vein premature atrial contractions at initial ablation for persistent atrial fibrillation. *Journal of Cardiovascular Electrophysiology*. 2021;32:224-234.
DOI:10.1111/jce.14830
88. Zhao Y, Di Biase L, Trivedi C, et al.: Importance of non-pulmonary vein triggers ablation to achieve long term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction. *Heart rhythm*. 2016; 13:141-149.
DOI:10.1016/j.hrthm.2015.08.029
89. Lin D, Frankel DS, Zado ES, et al.: Pulmonary vein antral isolation and nonpulmonary vein trigger ablation without additional substrate modification for treating longstanding persistent atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2012;23:806-813.
DOI:10.1111/j.1540-8167.2012.02307.x
90. Chang HY, Lo LW, Lin YJ, et al.: Long-term outcome of catheter ablation in patients with atrial fibrillation originating from nonpulmonary vein ectopy. *Journal of cardiovascular electrophysiology*. 2013;24: 250-258.
DOI:10.1111/jce.12036
91. Hung Y, Lo LW, Lin YJ, et al.: Characteristics and long-term catheter ablation outcome in long-standing persistent atrial fibrillation patients with non-pulmonary vein triggers. *International Journal of Cardiology*. 2017;241:205-211.
DOI:10.1016/j.ijcard.2017.04.050
92. Stavrakis S, Kulkarni K, Singh JP, Katritsis DG, Armoundas AA,: Autonomic modulation of cardiac arrhythmias:

- Methods to assess treatment and outcomes. *Clinical Electrophysiology*. 2020;6:467-483.
DOI:10.1016/j.jacep.2020.02.014
93. Hadaya J, Ardell JL.: Autonomic modulation for cardiovascular disease . *Frontiers in physiology*. 2020;11:617459.
DOI:10.3389/fphys.2020.617459
94. Tsai WC, Hung TC, Kusayama T, et al.: Autonomic modulation of atrial fibrillation . *jacc: Basic to translational science*; 2023. DOI:10.1016/j.jacbts.2023.03.019
95. Arora R.: Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: Implications for therapies targeting the atrial autonomic nervous system. . *Circulation: Arrhythmia and Electrophysiology*. 2012;5:850-859.
DOI:10.1161/CIRCEP.112.972273
96. Qin M, Zeng C, Liu X.: The cardiac autonomic nervous system: A target for modulation of atrial fibrillation. *Clinical Cardiology*. 2019; 42:644-652.
DOI:10.1002/clc.23190
97. Stavrakis S, Scherlag BJ, Po SS.: Autonomic modulation: An emerging paradigm for the treatment of cardiovascular diseases. *Circulation: Arrhythmia and Electrophysiology*. 2022;5:247-248.
DOI:10.1161/CIRCEP.112.972307
98. Mo BF, Zhang R, Yuan JL, et al.: Combined catheter ablation and left atrial appendage closure in atrial fibrillation patients with and without prior stroke. *Journal of Interventional Cardiology*. 2021;17:1533-1540.
DOI:10.1093/europace/euv070
99. Reddy VY, Akehurst RL, Amorosi SL, Gavaghan MB, Hertz DS, Holmes Jr DR. : Cost-effectiveness of left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation. *Stroke*. 2018;49:1464-1470.
DOI:10.1161/STROKEAHA.117.018825
100. Dar T, Yarlagadda B, Vacek J, Dawn B, Lakkireddy D.: Management of stroke risk in atrial fibrillation patients with bleeding on oral anticoagulation therapy-role of left atrial appendage closure, octreotide and more. *Journal of Atrial Fibrillation*. 2017;10:17-29. DOI:10.4022/jafib.1729
101. Dognin N, Salaun E, Champagne C, et al.: Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation. *Journal of Interventional Cardiac Electrophysiology*. 2021;1-13.
DOI:10.1007/s10840-021-01073-0
102. Wintgens L, Romanov A, Phillips K, et al.: Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. *EP Europace*. 2018;20:1783-1789.
DOI:10.1093/europace/euy025
103. Phillips KP, Pokushalov E, Romanov A, et al.: Combining watchman left atrial appendage closure and catheter ablation for atrial fibrillation: Multicentre registry results of feasibility and safety during implant and 30 days follow-up. . *Ep Europace*. 2018;20:949-955.
DOI:10.1093/europace/eux183

© 2023 Ifiora et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/106522>